



12-03-04

JPW. 1642

Express Mail No.: EV 498 828 395 US
Docket No. 3828-4001US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cohava Gelber Conformation No. 7840
Serial No.: 10/015,728 Group Art Unit: 1642
Filed: November 1, 2001 Examiner: Misook Yu
For: Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC)

EXPRESS MAIL CERTIFICATE

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following attached papers and fee

1. Supplemental Information Disclosure Statement (w/ duplicate)
2. Form PTO-1449
3. A copy of References 1-3 listed on Form PTO-1449
4. A copy of the Supplementary Partial European Search Report for a related European Patent Application
5. Return receipt postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on December 2, 2004 and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Albert Isles

(Typed or printed name of person mailing papers and fee)

(Signature of person mailing papers and fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281
(212) 415-8700 Telephone
(212) 415-8701 Facsimile



Express Mail No.: EV 498 828 395 US

Docket No. 3828-4001US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cohava Gelber

Conformation No. 7840

Serial No.: 10/015,728

Group Art Unit: 1642

Filed: November 1, 2001

Examiner: Misook Yu

For: Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. Copies of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) _____, filed _____, respectively.

- ☐ This document is being filed within three (3) months of the filing date of the application
Please charge the \$180 fee to Deposit Account No. 13-4500, Order No. ____.
- ☐ This document is being concurrently filed with the above-identified application
- ☐ This document is being concurrently filed with an Request for Continued Examination (RCE)
- ☒ This document is being filed prior to a first Office Action on the merits
- ☒ This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3828-4001US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: December 2, 2004

By:


Melissa B. Wenk
Registration No. 53,759

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile

27123

↑CUSTOMER NUMBER↑



Express Mail No.: EV 498 828 395 US

Page 1 of 1

FORM PTO-1449 INFORMATION DISCLOSURE CITATION				Attorney Docket: 3828-4001US1		Serial No.: 10/015,728	
				Applicant: Cohava GELBER			
				Filing Date: November 1, 2001		Group Art Unit: 1642	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent Number	Publication Date	Name	Class	Sub-Class	Filing Date
	1	5,614,373	March 25, 1997	Stahel	435	7.23	March 16, 1995
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Patent Number	Publication Date	Country	Class	Sub-Class	Translation
	2	WO 98/35985	August 20, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
OTHER DOCUMENTS (Including Author, Title, Date, etc.)							
	3	Rose et al., 1994, "A novel antigen defined by monoclonal antibody CR101 is associated with small cell lung carcinoma" <u>Hybridoma</u> 13(3):221-227.					
Examiner				Date Considered			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							